Final oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer.

Authors: Alexander Giesen, Gaëtan Devos, Lorenzo Tosco, Marcella Baldewijns, Thomas Gevaert, Karolien Goffin, Niloefar Ahmadi Bidakhvidi, Annouschka Laenen, Yannic Raskin, Carl Van Haute, Lieven Goeman, Gert de Meerleer, Charlien Berghen, Wout Devlies, Frank Claessens, Hendrik Van Poppel, Wouter Everaerts, Steven Joniau

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.394

Source: Full article

---

Abstract

394